• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Tocilizumab is superior to rituximab for treatment of rheumatoid arthritis in patients with low or absent B-cell lineage expression

byNeel MistryandTeddy Guo
June 25, 2021
in Chronic Disease
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Among patients categorized as B-cell poor group via RNA sequencing, tocilizumab had a significantly higher response rate than rituximab.

2. Likelihood of adverse events and serious adverse events were comparable between both treatment groups.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Rheumatoid arthritis is a chronic autoimmune condition with considerable morbidity and mortality worldwide. Although rituximab remains an important therapeutic option, mixed clinical response has been found regarding its efficacy. In patients with low or absent CD20 B cells, an alternative disease modifying anti-rheumatic drug (DMARD), such as tocilizumab, might be considered. This multicenter, randomized controlled trial aimed to compare the effect of tocilizumab with rituximab in patients with rheumatoid arthritis who had an inadequate response to anti-TNF stratified for synovial B-cell status. Primary outcome for this study was the difference in Clinical Disease Activity Index (CDAI) by 50% or more improvement (CDAI50%) at 16 weeks, while secondary outcomes included assessment of CDAI remission, Disease Activity Score (DAS28)-erythrocyte sedimentation rate (ESR) and DAS28-C reactive protein (CRP) response. Patients were deemed non-responders if they had CDAI50% less than 10.1 (CDAI-major treatment response; CDAI-MTR). According to study results, patients in the tocilizumab group had a significantly higher response rate compared with the rituximab group for CDAI50% in B-cell poor synovial biopsies with RNA sequencing. No statistical difference was found in patients histologically classified as B-cell poor. This study was limited by a binary design as histological classification was stratified either into B-cell poor or B-cell rich, as opposed to on a continuum. Nevertheless, this study represents the first biopsy-driven randomized clinical trial in rheumatoid arthritis.

Click to read the study in The Lancet

Relevant Reading: Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis

In-depth [randomized controlled trial]: Between Feb 28, 2013, and Jan 17, 2019, 212 patients were assessed for eligibility at 19 centers across 5 European countries. Included were those ≥ 18 years with previous unsuccessful treatment or intolerant to conventional synthetic DMARD therapy. Altogether, 164 patients were enrolled in the study (83 in the rituximab group and 81 in the tocilizumab group) and 161 were included in the analysis (79 B-cell poor, 64 B-cell rich, 9 germinal center positive patients, and 9 with unknown histology). The majority of enrolled patients (n=131, 77%) were female.

RELATED REPORTS

2 Minute Medicine Rewind April 9, 2022

2 Minute Medicine Rewind April 11, 2022

#VisualAbstract: Adding four doses of rituximab did not significantly improve event-free survival over standard of care in acute lymphoblastic leukaemia

99% (81 of 82) patients in the rituximab group and 92% (73 of 79) in the tocilizumab group completed treatment to primary endpoint at week 16. In patients histologically classified as B-cell poor, there was no statistically significant difference in CDAI50% between the rituximab group and the tocilizumab group (45% vs. 56%, 95% confidence interval [CI] -11 to 33, p=0.31). However, supplementary analysis of CDAI-MTR – defined as patients with CDAI50% but CDAI < 10.1 – showed a statistical significance between the rituximab group and tocilizumab group (24% vs. 46%, 95% CI 2-43, p=0.035). A similar pattern was found in synovial biopsies classified as B-cell poor with RNA sequencing, in which the tocilizumab group had a significantly higher response rate than the rituximab group for CDAI50% (63% vs. 36%, 95% CI 3-50, p=0.035). The response rates for several secondary outcomes were significantly higher in the tocilizumab group than with the rituximab group. No statistical difference between treatment groups was noticed for the occurrence of adverse events (70% rituximab vs. 80% tocilizumab, 95% CI -1 to 21) and serious adverse events (rituximab 7% vs. tocilizumab 10%, 95% -5 to 10). Findings from this study suggest that tocilizumab is superior to rituximab for rheumatoid arthritis patients with low or absent B-cell lineage expression.

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: arthritisb-cell poor rheumatoid arthritisrheumatoid arthritisrheumatologyrituximabTocilizumab
Previous Post

#VisualAbstract: Incidence and prevalence of melanomas and keratinocyte carcinomas have increased from 1990 to 2017

Next Post

Phase II O-12-M1: Melflufen plus dexamethasone showed benefits in long-term survival outcomes in relapsed/refractory multiple myeloma

RelatedReports

Weekly Rewinds

2 Minute Medicine Rewind April 9, 2022

May 9, 2022
Compliance-linked incentives increase infant immunizations rates in rural India
Weekly Rewinds

2 Minute Medicine Rewind April 11, 2022

April 11, 2022
#VisualAbstract: Adding four doses of rituximab did not significantly improve event-free survival over standard of care in acute lymphoblastic leukaemia
StudyGraphics

#VisualAbstract: Adding four doses of rituximab did not significantly improve event-free survival over standard of care in acute lymphoblastic leukaemia

April 8, 2022
Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial
Oncology

Biosimilar drugs undergo rigorous clinical testing and yield comparable outcomes to biologics

February 22, 2022
Next Post
Phase II O-12-M1: Melflufen plus dexamethasone showed benefits in long-term survival outcomes in relapsed/refractory multiple myeloma

Phase II O-12-M1: Melflufen plus dexamethasone showed benefits in long-term survival outcomes in relapsed/refractory multiple myeloma

Survival greater in cervical cancer patients undergoing abdominal hysterectomy compared to minimally invasive techniques: the LACC trial

2 Minute Medicine Rewind February 8, 2021

Quick Take: Association of Cereal, Gluten, and Dietary Fiber Intake With Islet Autoimmunity and Type 1 Diabetes

Higher consumption of refined grains other than white rice associated with a greater mortality and cardiovascular disease risk

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer
  • #VisualAbstract: Segmentectomy is superior to lobectomy for patients with early-stage non-small cell lung cancer
  • Several factors influence health programs conducted in the African American Church
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.